A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.
Kadcyla, manufactured by Roche, can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay, the National Institute for Health and Care Excellence (Nice) said.
The watchdog, which decides which new medicines are cost effective, said its guidance for the drug, also known as trastuzumab emtansine, was in draft form and is now up for public consultation.
If the recommendations are adopted, patients would have to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
More top news
Labour is facing a disastrous election night in Scotland, with the party in danger of finishing third behind the SNP and the Conservatives.
A Labour councillor who thought he had lost his seat was re-elected after a bundle of votes was found "under a Tory pile".
A sailor has been rescued after two months lost at sea, during which he was forced to eat seagulls for survival.